RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07422753, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Child-Pugh score ≤7.

    Inclusion criterion 8

  3. Major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dose, or unhealed wounds, ulcers, or fractures; tissue biopsy or other minor surgical procedures within 7 days prior to first dose (except venous catheter placement for intravenous infusion).

    Exclusion criterion 19

    Subjects with a history or ongoing Hepatitis C virus (HCV) infection are eligible. HCV-treated subjects must have completed treatment at least 1 month prior to start of study treatment. Subjects with Hepatitis B virus (HBV) are eligible if they meet the following: Patients with HBV viral load ≥10,000 IU/mL must receive anti-HBV therapy concurrent with HCC treatment; subjects on anti-HBV therapy with viral load <10,000 IU/mL should continue the same therapy throughout study treatment. Subjects who are anti-HBc positive, HBsAg negative, anti-HBs negative or positive, and with HBV viral load <10,000 IU/mL do not require anti-HBV prophylaxis.

    Exclusion criterion 21

    Active tuberculosis (TB), currently on anti-TB treatment or received anti-TB treatment within 1 year prior to first dose.

    Exclusion criterion 22

    Prior treatment with any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA-4 antibody, or other immunotherapy.

    Exclusion criterion 31

  4. ECOG Performance Status score of 0\~1.

    Inclusion criterion 4

  5. At least one measurable lesion according to RECIST 1.1 criteria.

    Inclusion criterion 9

  6. Known human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibodies), known syphilis infection.

    Exclusion criterion 23

    Diagnosis of other malignancies within 5 years prior to first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or carcinoma in situ. If diagnosis of other malignancy was more than 5 years prior, pathological/cytological diagnosis of recurrent/metastatic lesions is required.

    Exclusion criterion 30

  7. Pregnant or breastfeeding female patients.

    Exclusion criterion 34

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07422753, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign and date a written informed consent form prior to the implementation of any trial-related procedures.
  • Patients with clinically confirmed unresectable or metastatic hepatocellular carcinoma (HCC).
  • Male or female, ≥18 years old, ≤75 years old.
  • ECOG Performance Status score of 0\~1.
  • Expected survival time >3 months.
  • Barcelona Clinic Liver Cancer (BCLC) Stage B or C for unresectable HCC.
  • Suitable for Transarterial Chemoembolization (TACE) treatment.
  • Child-Pugh score ≤7.
  • At least one measurable lesion according to RECIST 1.1 criteria.

Exclusion Criteria:

  • Previous histological/cytological confirmation of HCC with fibrolamellar, sarcomatoid, or cholangiocarcinoma components.
  • History of liver transplantation or hepatic encephalopathy.
  • Diffuse liver cancer.
  • Inability to tolerate TACE or prior history of TACE treatment.
  • Prior treatment with Transarterial Chemoembolization (TACE), Transarterial Embolization (TAE), or Transarterial Radioembolization (TARE).
  • Prior systemic anti-tumor therapy or radiotherapy for HCC.
  • Portal vein main trunk tumor thrombus without adequate collateral circulation, or concurrent involvement of the superior mesenteric vein; inferior vena cava tumor thrombus.
  • Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage.
  • Any history of renal disease or nephrotic syndrome.
  • History of esophageal or gastric variceal bleeding due to portal hypertension within the past 6 months; presence of severe (Grade 3) varices on endoscopy known within 3 months prior to first dose; evidence of portal hypertension (including splenomegaly on imaging) with high risk of bleeding as assessed by the investigator.
  • Any life-threatening bleeding event within the past 3 months, requiring transfusion, surgery, local therapy, or continuous medication.
  • Arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other severe thromboembolism. Except for catheter-related thrombosis from implanted ports or superficial venous thrombosis if stable under routine anticoagulation.
  • Significant bleeding tendency or coagulopathy, or undergoing thrombolytic therapy.
  • Prophylactic use of low-dose low molecular weight heparin (e.g., enoxaparin 40 mg/day) is allowed, but not vitamin K antagonists (e.g., warfarin).
  • Requirement for long-term use of platelet function inhibitors such as aspirin, dipyridamole, or clopidogrel.
  • Uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical therapy), history of hypertensive crisis or hypertensive encephalopathy.
  • Symptomatic congestive heart failure (New York Heart Association Class II-IV), symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome, or corrected QT interval (QTc) >500 ms on screening ECG (using Fridericia's formula).
  • History of gastrointestinal perforation and/or fistula, intestinal obstruction (including incomplete obstruction requiring parenteral nutrition) within the past 6 months; extensive intestinal resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic long-term diarrhea.
  • Major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dose, or unhealed wounds, ulcers, or fractures; tissue biopsy or other minor surgical procedures within 7 days prior to first dose (except venous catheter placement for intravenous infusion).
  • History or current presence of pulmonary diseases such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, or severe impaired lung function.
  • Subjects with a history or ongoing Hepatitis C virus (HCV) infection are eligible. HCV-treated subjects must have completed treatment at least 1 month prior to start of study treatment. Subjects with Hepatitis B virus (HBV) are eligible if they meet the following: Patients with HBV viral load ≥10,000 IU/mL must receive anti-HBV therapy concurrent with HCC treatment; subjects on anti-HBV therapy with viral load <10,000 IU/mL should continue the same therapy throughout study treatment. Subjects who are anti-HBc positive, HBsAg negative, anti-HBs negative or positive, and with HBV viral load <10,000 IU/mL do not require anti-HBV prophylaxis.
  • Active tuberculosis (TB), currently on anti-TB treatment or received anti-TB treatment within 1 year prior to first dose.
  • Known human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibodies), known syphilis infection.
  • Active or poorly controlled severe infection. Severe infection within 4 weeks prior to first dose, including but not limited to hospitalization for infection complications, bacteremia, or severe pneumonia.
  • Active autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is allowed. Known history of primary immunodeficiency. Subjects with only positive autoimmune antibodies should be evaluated by the investigator to confirm the absence of autoimmune disease.
  • Use of immunosuppressive medication within 4 weeks prior to first dose, excluding intranasal, inhaled, topical corticosteroids, or systemic corticosteroids at physiologic doses (not exceeding 10 mg/day prednisone or equivalent). Temporary use of corticosteroids for conditions like asthma or COPD is allowed.
  • Administration of a live attenuated vaccine within 4 weeks prior to first dose or planned during the study.
  • Use of traditional Chinese medicine with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukin; except for local use to control pleural or ascitic fluid) within 2 weeks prior to first dose.
  • Uncontrolled/uncorrectable metabolic disorders, other non-malignant organ/systemic diseases, or cancer-related sequelae that could lead to higher medical risk and/or uncertainty in survival evaluation.
  • Diagnosis of other malignancies within 5 years prior to first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or carcinoma in situ. If diagnosis of other malignancy was more than 5 years prior, pathological/cytological diagnosis of recurrent/metastatic lesions is required.
  • Prior treatment with any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA-4 antibody, or other immunotherapy.
  • Known allergy to Sintilimab, Bevacizumab, or their excipients, or history of severe hypersensitivity to other monoclonal antibodies.
  • Treatment with other investigational agents within 4 weeks prior to first dose.
  • Pregnant or breastfeeding female patients.
  • Any other acute or chronic disease, psychiatric condition, or abnormal laboratory finding that, in the investigator's judgment, may increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results, and make the patient unsuitable for entry into this study.

Quoted from ClinicalTrials.gov, NCT07422753, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07422753, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07422753